Free Trial
OTCMKTS:ATBPF

Antibe Therapeutics (ATBPF) Stock Price, News & Analysis

Antibe Therapeutics logo
$0.22 0.00 (0.00%)
As of 04/16/2025

About Antibe Therapeutics Stock (OTCMKTS:ATBPF)

Key Stats

Today's Range
$0.22
$0.22
50-Day Range
$0.22
$0.22
52-Week Range
$0.11
$0.89
Volume
N/A
Average Volume
27,352 shs
Market Capitalization
$11.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Receive ATBPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATBPF Stock News Headlines

APLIF Appili Therapeutics Inc.
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
Antibe Announces Appointment of Receiver
Antibe Announces Appointment of Receiver
Antibe Provides Update on CCAA Proceedings
Antibe Announces TSX Delisting Review
See More Headlines

ATBPF Stock Analysis - Frequently Asked Questions

Antibe Therapeutics' stock was trading at $0.2156 on January 1st, 2025. Since then, ATBPF stock has increased by 0.0% and is now trading at $0.2156.
View the best growth stocks for 2025 here
.

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02.

Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/13/2023
Today
5/24/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ATBPF
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
0.37

Miscellaneous

Free Float
48,238,000
Market Cap
$11.42 million
Optionable
Not Optionable
Beta
0.51
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (OTCMKTS:ATBPF) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners